ITMN does not appear to be confident of prompt FDA approval for Esbriet (pirfenidone) insofar as the commercial infrastructure for a US launch is not yet in place. This is in stark contrast to the way DNDN handled the pre-commercialization planning for Provenge.
Market Data 
Markets 
AI
